Raffaello Sostegni
Overview
Explore the profile of Raffaello Sostegni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
759
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banche G, Allizond V, Sostegni R, Lavagna A, Bergallo M, Sidoti F, et al.
New Microbiol
. 2015 Jul;
38(3):357-67.
PMID: 26147146
The difficulties involved in detecting and enumerating Mycobacterium avium subsp. paratuberculosis (MAP) as a pathogen potentially involved in Crohn's disease (CD) are well known. This study aimed to improve this...
2.
Monterubbianesi R, Aratari A, Armuzzi A, Daperno M, Biancone L, Cappello M, et al.
J Crohns Colitis
. 2014 Jan;
8(8):852-8.
PMID: 24472490
Background: Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present...
3.
Armuzzi A, Biancone L, Daperno M, Coli A, Pugliese D, Annese V, et al.
Dig Liver Dis
. 2013 May;
45(9):738-43.
PMID: 23683530
Background And Aims: The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute...
4.
Daperno M, Sostegni R, Rocca R
Dig Liver Dis
. 2012 Jul;
44(9):721-2.
PMID: 22809958
No abstract available.
5.
Pellicano R, Sostegni R, Sguazzini C, Reggiani S, Astegiano M
Acta Biomed
. 2011 Nov;
82(1):74-6.
PMID: 22069960
Crohn's disease (CD) is a chronic inflammatory disease that affects both the small and large intestine in approximately 40% of cases, solely the ileum or the colon in 30% and...
6.
Saibeni S, Bollani S, Losco A, Michielan A, Sostegni R, Devani M, et al.
Dig Liver Dis
. 2011 Nov;
44(2):123-7.
PMID: 22051323
Background: Methotrexate is considered a treatment for Crohn's disease, whilst few data in ulcerative colitis are available. Aim: To evaluate frequency, indications, efficacy and safety of methotrexate in inflammatory bowel...
7.
Serpe L, Canaparo R, Daperno M, Sostegni R, Martinasso G, Muntoni E, et al.
Eur J Pharm Sci
. 2010 Feb;
39(5):428-36.
PMID: 20138213
Standard treatment for inflammatory bowel diseases (IBD) necessitates frequent intake of anti-inflammatory and/or immunosuppressive drugs, leading to significant adverse events. To evaluate the role solid lipid nanoparticles (SLN) play as...
8.
Rigazio C, Ercole E, Laudi C, Daperno M, Lavagna A, Crocella L, et al.
Scand J Gastroenterol
. 2009 Jan;
44(5):585-93.
PMID: 19148846
Objective: Abdominal bowel ultrasound (US) is widely used in the management of Crohn's disease (CD). The aim of this study was to evaluate the prognostic role of bowel-wall US morphology...
9.
Viklund I, Kuznetsov N, Lofberg R, Daperno M, Sostegni R, Astegiano M, et al.
Int J Colorectal Dis
. 2008 Jul;
23(10):921-30.
PMID: 18654788
Background And Aims: Inflammatory bowel disease (IBD) is a complex inflammatory disease of the gastrointestinal tract with unknown cause that lacks molecular markers for diagnosis. Crohn's disease (CD) and ulcerative...
10.
Sostegni R, Pera A, Daperno M, Rocca R
Recenti Prog Med
. 2008 Apr;
99(1):10-8.
PMID: 18389866
The medical management of inflammatory bowel disease has considerably changed thanks to the biologic agents coming. In this review a critical evaluation of controlled studies with biologic agents for the...